Neuren Pharmaceuticals Ltd
ASX:NEU

Watchlist Manager
Neuren Pharmaceuticals Ltd Logo
Neuren Pharmaceuticals Ltd
ASX:NEU
Watchlist
Price: 12.55 AUD -0.4% Market Closed
Market Cap: 1.6B AUD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+25%
Revenue
Forecast
+8%
Operating Income
Forecast
+8%
Net Income
Forecast
+12%

Wall Street
Price Targets

NEU Price Targets Summary
Neuren Pharmaceuticals Ltd

Wall Street analysts forecast NEU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NEU is 26.22 AUD with a low forecast of 20.2 AUD and a high forecast of 32.34 AUD.

NEU Lowest Forecast
Wall Street Target
20.2 AUD
61% Upside
NEU Average Forecast
Wall Street Target
26.22 AUD
109% Upside
NEU Highest Forecast
Wall Street Target
32.34 AUD
158% Upside
Lowest
Price Target
20.2 AUD
61% Upside
Average
Price Target
26.22 AUD
109% Upside
Highest
Price Target
32.34 AUD
158% Upside
Neuren Pharmaceuticals Ltd Competitors:
Price Targets
NEULANDLAB
Neuland Laboratories Ltd
50% Upside
C
214370
Caregen Co Ltd
45% Upside
G
GLS
Glenmark Life Sciences Ltd
10% Upside
1795
Lotus Pharmaceutical Co Ltd
75% Upside
NEULANDLAB
Neuland Laboratories Ltd
50% Upside
C
214370
Caregen Co Ltd
45% Upside
G
GLS
Glenmark Life Sciences Ltd
10% Upside
1795
Lotus Pharmaceutical Co Ltd
75% Upside
D
DPHARMA
Duopharma Biotech Bhd
28% Upside
4577
Daito Pharmaceutical Co Ltd
1% Upside
CLSD
Clearside Biomedical Inc
509% Upside
4540
Tsumura & Co
25% Upside

Revenue
Forecast

Revenue Estimate
Neuren Pharmaceuticals Ltd

For the last 8 years the compound annual growth rate for Neuren Pharmaceuticals Ltd's revenue is 82%. The projected CAGR for the next 4 years is -11%.

82%
Past Growth
-11%
Estimated Growth
Estimates Accuracy
-14%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Neuren Pharmaceuticals Ltd

The compound annual growth rate of Neuren Pharmaceuticals Ltd's operating income for the next 4 years is -20%.

N/A
Past Growth
-20%
Estimated Growth
Estimates Accuracy
-16%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Neuren Pharmaceuticals Ltd

The compound annual growth rate of Neuren Pharmaceuticals Ltd's net income for the next 3 years is -18%.

N/A
Past Growth
-18%
Estimated Growth
Estimates Accuracy
-25%
Average Miss
What are analyst estimates?

See Also

Summary
NEU intrinsic value, competitors valuation, and company profile.
DCF Valuation
NEU stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NEU stock valuation using valuation multiples.
Wall Street Estimates
NEU price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NEU stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NEU's stock price target?
Price Target
26.22 AUD

According to Wall Street analysts, the average 1-year price target for NEU is 26.22 AUD with a low forecast of 20.2 AUD and a high forecast of 32.34 AUD.

What is Neuren Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
-11%

For the last 8 years the compound annual growth rate for Neuren Pharmaceuticals Ltd's revenue is 82%. The projected CAGR for the next 4 years is -11%.

What is Neuren Pharmaceuticals Ltd's Operating Income forecast?
Projected CAGR
-20%

The compound annual growth rate of Neuren Pharmaceuticals Ltd's operating income for the next 4 years is -20%.

What is Neuren Pharmaceuticals Ltd's Net Income forecast?
Projected CAGR
-18%

The compound annual growth rate of Neuren Pharmaceuticals Ltd's net income for the next 3 years is -18%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 240,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.